Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−9.234EUR
3.06 M
About NEUBASE THERAPEUTICS INC
Sector
CEO
Todd P. Branning
Headquarters
Pittsburgh
Website
Founded
2009
FIGI
BBG005YP1JT1
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BER exchange NEUBASE THERAPEUT. DL-,01 stocks are traded under the ticker O7P.
Yes, you can track NEUBASE THERAPEUT. DL-,01 financials in yearly and quarterly reports right on TradingView.
NEUBASE THERAPEUT. DL-,01 is going to release the next earnings report on May 31, 2024. Keep track of upcoming events with our Earnings Calendar.
O7P net income for the last quarter is −1.72 M EUR, while the quarter before that showed −3.16 M EUR of net income which accounts for 45.48% change. Track more NEUBASE THERAPEUT. DL-,01 financial stats to get the full picture.
No, O7P doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, O7P shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEUBASE THERAPEUT. DL-,01 stock right from TradingView charts — choose your broker and connect to your account.